A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)

被引：13
|
作者：
Slomovitz, B. M.
Lu, K. H.
Johnston, T.
Munsell, M.
Ramondetta, L. M.
Broaddus, R. R.
Coleman, R. L.
Walker, C.
Gershenson, D. M.
Burke, T. W.
Wolf, J.
机构：
[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5502
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study
    Wei, Andrew H.
    Sadawarte, Sonali
    Catalano, John
    Schwarer, Anthony P.
    Avery, Sharon
    Patil, Sushrut S.
    Spencer, Andrew
    BLOOD, 2010, 116 (21) : 1352 - 1353
  • [32] Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    Milowsky, M. I.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Trout, A.
    Flaherty, A.
    Gerst, S.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [33] Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium
    Milowsky, M. I.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I.
    Flaherty, A.
    Tickoo, S.
    Al-Ahmadie, H.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer
    Acevedo-Gadea, Carlos
    Santin, Alessandro D.
    Higgins, Susan A.
    Urva, Shweta
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Rutherford, Thomas
    Schwartz, Peter E.
    Abu-Khalaf, Maysa M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (03) : 528 - 533
  • [35] A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
    Giessinger, S.
    Amato, R. J.
    Jac, J.
    Saxena, S.
    Willis, J. P.
    Chiang, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.
    Ghobrial, Irene M.
    Gertz, Morie A.
    LaPlant, Betsy
    Camoriano, John Kelly
    Hayman, Suzanne R.
    Lacy, Martha
    Chuma, Stacey
    Harris, Brianna
    Boswell, Erica
    Banwait, Ranjit
    Sheehy, Patricia
    Ansell, Stephen Maxted
    DeAngelo, Daniel J.
    Dispenzieri, Angela
    Bergsagel, Leif
    Reeder, Craig B.
    Anderson, Kenneth Carl
    Richardson, Paul Gerard Guy
    Treon, Steven P.
    Witzig, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Brigette B. Y. Ma
    Vivian W. Y. Lui
    Edwin P. Hui
    Cecilia P. Y. Lau
    Kakiu Ho
    Margaret H. L. Ng
    S. H. Cheng
    Sai-Wah Tsao
    Anthony T. C. Chan
    Investigational New Drugs, 2010, 28 : 413 - 420
  • [38] SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
    Ou, Sai-Hong Ignatius
    Moon, James
    Garland, Linda L.
    Mack, Philip C.
    Testa, Joseph R.
    Tsao, Anne S.
    Wozniak, Antoniette J.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 387 - 391
  • [39] A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
    Kim, S. J.
    Shin, D. -Y.
    Kim, J. S.
    Yoon, D. H.
    Lee, W. S.
    Lee, H.
    Do, Y. R.
    Kang, H. J.
    Eom, H. S.
    Ko, Y. H.
    Lee, S. H.
    Yoo, H. Y.
    Hong, M.
    Suh, C.
    Kim, W. S.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 712 - 718
  • [40] A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.
    Mayer, I. A.
    Means-Powell, J.
    Shyr, Y.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (24) : 677S - 677S
12345